On June 30, 2021 Cerus Corporation (NASDAQ: CERS) reported an agreement with LifeSouth Community Blood Centers (LifeSouth) to serve as a production partner for INTERCEPT Fibrinogen Complex, the company’s pathogen reduced cryoprecipitated fibrinogen complex product (Press release, Cerus, JUN 30, 2021, View Source [SID1234584526]). LifeSouth is the fifth production partner for INTERCEPT Fibrinogen Complex, enabling the initial commercial launch of the product to expand into the state of Florida.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are delighted to add LifeSouth as a blood center manufacturing partner for INTERCEPT Fibrinogen Complex," stated Elan Weiner, general manager of Cerus Therapeutics. "The initial market response has been enthusiastic and as we gear up for a nationwide launch in 2022 following anticipated BLA approvals, we are happy to be able to offer this product in Florida through our partnership. LifeSouth’s strong presence throughout the Southeast will help ensure we have the ability to easily deliver product to hospitals in the region," Mr. Weiner continued.

As the third most populous state in the country, Florida is home to more than 30 Level 1, Level 2 and Pediatric trauma centers. Together with the other four states that are a part of the initial launch (California, Louisiana, Texas and Wisconsin), INTERCEPT Fibrinogen Complex will be available for use to nearly one-third of the U.S. population.

"We believe INTERCEPT Fibrinogen Complex is an exciting innovation in transfusion medicine, and we are pleased to partner with Cerus in the Florida market. Tools to help manage bleeding patients help fill a significant unmet need, and we are excited to contribute to making INTERCEPT Fibrinogen Complex available," noted Kimberly E. Kinsell, president and chief executive officer of LifeSouth.